The Medical House PLC (TMH) is a group of companies which
specialises in the design, development, licensing and supply
of innovative medical devices for global pharmaceutical, biotechnology
and orthopaedic industry clients.
The group is focused on drug delivery technologies through
its Medical House Products Ltd subsidiary.
Founded in 1987, TMH was admitted to London Stock Exchange's
Alternative Investment Market (A.I.M.) in 2000.
The group's quality management systems are certified as compliant
with ISO 9001: 2000 and ISO 13485:2003 and several of its
medical device products have successfully achieved European
CE-mark and United States FDA 510(k) approvals.
Needle-free delivery Systems - Medical House Products
Ltd
The market for products for people with diabetes in the
UK alone is over 500,000 who need to inject insulin on a
daily basis. The mhi-500
is sold and marketed through the www.insulinjet.com
web-site. The mhi-500
received a CE mark in December 2001 and sales began in January
2002.
In November 2002 The Medical House received Drug Tariff
Approval for the mhi-500 (effective 1st Jan 2003). This
effectively means that the mhi-500 is available free to
diabetics in the UK provided they have a prescription from
their G.P. In order to become the first and only needle
free injection system on the Drug Tariff the Medical House
had to demonstrate cost equivalence as well as bio equivalence
to the present needle based systems.
In June 2002 an exclusive worldwide agreement was signed
with BioPartners GmbH for the development of a new growth
hormone drug. The stimulus for the development of needle-free
injection devices is patient aversion to and wariness of
needles. The consequence of this is patents can be reluctant
to comply fully with their prescribed drug treatment regime.
This can cause the treatment to be less effective and can
lead to expensive subsequent surgery. The objective of needle-free
devices is to encourage better compliance with a treatment
regime, with obvious benefits to the patents and the healthcare
provider.
Medical Devices Design Division
Creative
Medical Design entered into a licence agreement with
Bioject Inc in April 2001. Under this agreement the Company
was commissioned to develop a 2nd generation device, for
use with insulin, which became the mhi-500. Under the agreement
the intellectual property rights (IPR) are jointly held
with Bioject. The Medical House's rights are limited to
Insulin and Dental Anaesthesia throughout Europe.
Creative
Medical Design works closely with the customers of Eurocut
in the development of orthopaedic instruments, and Medical
House Products customers for developing Bespoke Drug Delivery
Solutions. The highly developed skills of Creative
Medical Design's experienced operators and its integrated
Unigraphics CAD-CAM system provide the capability to cope
with the complexity and sophistication of virtually any
product and to add value to customers' designs. These skills
have been enhanced by the acquisition of a rapid prototyping
machine, enabling prototypes of all types of medical devices
to be produced literally overnight.
Creative
Medical Design has been a key part of the group's strategy
by utilising its skills and facilities to develop the medical
products in the Products Division.
The skills of the designers are complemented by the investments
which have been made in an advanced integrated CADCAM system
to design and model he most complex and sophisticated instruments
an devices. Together with the investment in a rapid prototyping
capability this enables the company to produce a working
prototype product within 24 hours of initial outline.
This technology was acquired from Medisys in October 2000
and The Medical House took charge of the project in January
2001. Since then we have developed a device which detects
ammonia, known to be released by helicobacter pylori (the
bacteria responsible for certain gastric complaints including
ulcers). The device is now being trialled under a variety
of different conditions, in order to provide the data needed
to market the test.
In comparison to conventional testing the Hyperlyser
represents a simple, non-invasive and cheap alternative,
for which the world market has tremendous potential. Our
present intention is to make initial quantities in the UK,
to be distributed in the UK and overseas through already
identified parties.
Group Companies
The Medical House PLC
199 Newhall Road
Attercliffe
Sheffield
S9 2QJ
United Kingdom
Telephone: +44 (0)114 261 9011
Fax: +44 (0)114 243 1597
web site: www.themedicalhouse.com
--------------------------------------------------------------------------------
Medical House Products Ltd (drug delivery)
199 Newhall Road
Attercliffe
Sheffield
S9 2QJ
United Kingdom
Telephone: +44 (0) 114 261 9011
Fax: +44 (0) 114 243 1597
Web site: www.tmh-drugdelivery.com
Creative Medical Design Ltd (medical device design)
199 Newhall Road
Attercliffe
Sheffield
S9 2QJ
United Kingdom
Telephone: +44 (0) 114 261 9011
Fax: +44 (0) 114 261 1575
Web site: www.creativemedicaldesign.co.uk
